Introduction: Remdesivir, a nucleotide analogue that competes ATP utilization with RNA dependent RNA Polymerase (RdRp) that interfere viral RNA polymerase that inhibit RNA synthesis and viral replication. It was widely used in patients of COVID-19 with different results in different stage of disease. Methods: Present study is an observational cross sectional study to effect of remdesivir on patients of COVID-19 to compare early versus late use of remdesivir in hospitalized patients between 01/09/2020 to 10/09/2021. Results: Total 99 cases of COVID-19 hospitalized at PMCH Udaipur during study period, the mean age of the patients was 58.26 years, majority were males (75%). Most Common presenting complaint was shortness of breath (67%). Hypertension (38%) was the most common morbidity. On clinical examination of patients 61% were febrile and 61% had tachypnoea. Overall, in hospital mortality observed was 22.22%. The lowest mortality (9.09%) was observed in group who received remdesivir in between 6-10 days of onset of illness while the group with initiation of remdesivir in between 1-5 days of illness had 26.67% mortality. The difference of mortality between of different group was found to be statistically significant(p=0.03). Whereas age, gender, underlying co morbidities, HRCT score before remdesivir administration did not show statistically significant association. Conclusions: In our study, the use of remdesivir was found to be effective in early recovery and reducing mortality in patient of COVID-19 and best results were observed when remdesivir wasinitiated in early course of illness.